The goal of this clinical research study is to find the optimum biologic dose
(OBD) of PEG Intron that can be given as a treatment for patients with ovarian,
peritoneal, or fallopian tube cancer. Researchers hope to find out if PEG
Intron will help shrink or slow the growth of tumors in patients who are
considered resistant to platinum drugs. The safety of this drug will also be
studied